Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.56 |
| ▸ | AHR | P35869 | 3/20 | 0.49 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779539 | 1.00 | SMYD3 (0.56) | SMYD3AHRCMA1GAA | |
| SCHEMBL30364069 | 0.85 | SMYD3 (0.59) | SMYD3AHRCMA1GAA | |
| Hydrochloric Acid SCHEMBL29779521 | 0.84 | SMYD3 (0.57) | SMYD3AHRCMA1GAA | |
| SCHEMBL622063 | 0.83 | SMYD3 (0.56) | SMYD3AHRCMA1 | |
| SCHEMBL31210109 | 0.83 | SMYD3 (0.56) | SMYD3AHRCMA1 | |
| SCHEMBL4218125 | 0.81 | SMYD3 (0.52) | SMYD3AHRCMA1 | |
| SCHEMBL5792436 | 0.81 | SMYD3 (0.52) | SMYD3AHRCMA1 | |
| SCHEMBL8232914 | 0.81 | SMYD3 (0.52) | SMYD3AHRCMA1 | |
| SCHEMBL1162689 | 0.80 | SMYD3 (0.43) | SMYD3AHRCMA1GAA | |
| SCHEMBL3205007 | 0.80 | AHR (0.49) | SMYD3AHRCMA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-115028619-A | SMYD inhibitors | EPIZYME股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-107072205-B | SMYD inhibitors | EPIZYME股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| CN-107072205-A | SMYD inhibitors | EPIZYME股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3193600-A1 | SMYD INHIBITORS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016040505-A1 | SMYD INHIBITORS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2012061597-A1 | ALPHA-GLUCOSIDASE BINDERS AND METHODS OF THEIR USE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885AHR 1930/4885CMA1 2943/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885AHR 2465/4885CMA1 2605/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885AHR 2472/4885CMA1 2659/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885AHR 1942/4885CMA1 2308/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885AHR 2482/4885CMA1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.